Abstracts Archive - Page 1559 of 2607 - ACR Meeting Abstracts

Abstract Number: 2576 • 2017 ACR/ARHP Annual Meeting
Caspase 8 in Dendritic Cells Suppresses IRF5 Activation through Endosomal TLR Signaling to Prevent SLE-like Disease
FuNien Tsai¹, Harris Perlman² and Carla Cuda², ¹Medicine-Rheumatology, Northwestern University-Feinberg School of Medicine, Chicago, IL, ²Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Previous studies implicate dendritic cells (DCs) in the pathogenesis of systemic lupus erythematosus (SLE), yet the mechanisms underlying this involvement are not yet clear.…
Abstract Number: 2577 • 2017 ACR/ARHP Annual Meeting
Segmented Filamentous Bacteria Colonization Exacerbate Lupus Nephritis in NZM2410 Mice and Causes an Expansion of Intestinal Group 3 Innate Lymphoid Cells
Giancarlo R. Valiente¹, Jeffrey Hampton², Takuma Wada³, Perry Blough³, William Willis⁴, Nicholas A. Young⁴, Lai-Chu Wu⁵ and Wael Jarjour⁶, ¹Rheumatology & Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University, Columbus, OH, ⁴Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Biological Chemistry and Pharmacology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Department of Rheumatology/Medicine, Ohio State University, Columbus, OH
Title: Segmented Filamentous Bacteria Colonization Exacerbate Lupus Nephritis in NZM2410 Mice and Causes an Expansion of Intestinal Group 3 Innate Lymphoid Cells Background/Purpose: Innate Lymphoid…
Abstract Number: 2578 • 2017 ACR/ARHP Annual Meeting
RAB4A Protects from Antinuclear Antibody Production and Nephritis in the Pristane-Induced Model of SLE
Gourav Choudhary¹, Nick Huang², Thomas Winans³, Ryan Kelly⁴, Sarah Blair³, Miguel Beckford³ and Andras Perl², ¹Department of Biochemistry and Mol. Biology, SUNY Upstate Medical University, Syracuse, NY, ²Medicine, SUNY Upstate Medical University, Syracuse, NY, ³SUNY Upstate Medical University, Syracuse, NY, ⁴SUNY, Syracuse, NY
Background/Purpose: Systematic lupus erythematosus (SLE) is a multisystem chronic inflammatory disease characterized by circulating antinuclear autoantibodies and dysfunction of B cells, T cells, and dendritic…
Abstract Number: 2579 • 2017 ACR/ARHP Annual Meeting
Rock-Mediated Pkca Nuclear Translocation Is Important in Neutrophil Netosis and UVB Induced-Skin Inflammation
Ming-Lin Liu¹, Yubin Li², Meena Sharma³ and Victoria P. Werth⁴, ¹Department of Dermatology,, Philadelphia V.A. Medical Center, Philadelphia, PA, ²Dermatology, University of pennsylvania, Philadelphia, PA, ³Department of Dermatology, Philadelphia V.A. Medical Center, Philadelphia, PA, ⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Neutrophils are the most abundant circulating leukocytes and the earliest inflammatory cells to be recruited to the site of photodamage after ultraviolet B (UVB)…
Abstract Number: 2580 • 2017 ACR/ARHP Annual Meeting
Exploiting Inhibition of PD1 Signaling in a Murine Model of Anti-SSA/Ro Associated Congenital Heart Block
Robert M. Clancy¹, Glenn Fishman¹, Colin Phoon¹, Marc Halushka², Tanisha Jackson¹, Kimberly Robins¹ and Jill P. Buyon¹, ¹NYU School of Medicine, New York, NY, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The most serious manifestation of fetal exposure to maternal anti-Ro antibodies is the development of heart block. This work addresses the hypothesis that fetal…
Abstract Number: 2581 • 2017 ACR/ARHP Annual Meeting
Safety of Hydroxychloroquine Withdrawal in Older Adults with Systemic Lupus Erythematosus
Anna Zezon¹, Peter M. Izmirly², Nicole Bornkamp³, Chung-E Tseng⁴, H. Michael Belmont³, Anca Askanase⁵, Jane E. Salmon⁶, Michael Lockshin⁷ and Jill P. Buyon³, ¹Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, ²New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴Rheumatology, New York University School of Medicine, New York, NY, ⁵Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY
Background/Purpose: Although hydroxychloroquine (HCQ) is a mainstay of treatment for patients with Systemic Lupus Erythematosus (SLE), ocular toxicity can result from accumulated exposure. The introduction…
Abstract Number: 2582 • 2017 ACR/ARHP Annual Meeting
Compliance and Persistence with Hydroxychloroquine in Patients with Systemic Lupus Erythematosus
Seong-Min Kweon¹, Seung-Geun Lee², Ji-Heh Park², Eun-Kyoung Park³, Yun-Kyung Kim⁴, Geun-Tae Kim⁵ and Dong Hyun Sohn⁶, ¹Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea, Busan, Korea, Republic of (South), ²Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, Republic of (South), ⁴Internal Medicine, Kosin University College of Medicine, Busan, South Korea, Busan, Korea, Republic of (South), ⁵Kosin University College of Medicine, Busan, Korea, Republic of (South), ⁶Microbiology and Immunology, Pusan National University School of Medicine, Yangsan, Korea, Republic of (South)
Compliance and persistence with hydroxychloroquine in patients with systemic lupus erythematosusBackground/Purpose: Lifelong treatment with hydroxychloroquine (HCQ) is now recommended for all patients with systemic lupus…
Abstract Number: 2583 • 2017 ACR/ARHP Annual Meeting
Effects of Mycophenolate Mofetil (MMF) on Immunogenicity of Ppsv-23 Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases
Priya Prakash¹, Mark Tratenberg², Slavica Bobic³, Rui Zhang⁴, Kirk Sperber⁵, Amy Wasserman⁶ and Julia Ash⁷, ¹Medicine-Rheumatology, New York Medical College / Westchester Medical Center, Valhalla, NY, ²New York Medical College / Westchester Medical Center, valhalla, NY, ³Medicine-Rheumatology, New York Medical College / Westchester Medical Center, valhalla, NY, ⁴Medicine -Rheumatology, New York Medical College / Westchester Medical Center, valhalla, NY, ⁵New York Medical College / Westchester Medical Center, Valhalla, NY, ⁶Medicine - Rheumatology, New York Medical College / Westchester Medical Center, VALHALLA, NY, ⁷Medicine -Rheumatology, New York Medical College / Westchester Medical Center, Valhalla, NY
Background/Purpose: MMF suppresses immune function by inhibiting T cell dependent and independent humoral immune responses. This study investigates the humoral immune response to the PPSV23…
Abstract Number: 2584 • 2017 ACR/ARHP Annual Meeting
Apremilast in Patients with Lupus Rashes
Robert S. Katz, Rush University Medical Center, Chicago, IL
Background/Purpose: Apremilast has been approved by the FDA for treatment of psoriasis and psoriatic arthritis. Because side effects are few, we decided to use it…
Abstract Number: 2585 • 2017 ACR/ARHP Annual Meeting
Safety Profile in SLE Patients Treated with Atacicept in a Phase IIb Study (ADDRESS II) and Its Extension Study
Joan T. Merrill¹, Daniel J. Wallace², Cristina Vazquez-Mateo³, Amy H. Kao³, Patricia Fleuranceau-Morel³, Peter Chang⁴ and David A. Isenberg⁵, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Cedars-Sinai Medical Center, UCLA, Los Angeles, CA, ³EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁴EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA, ⁵Centre for Rheumatology Research, University College London, London, England
Background/Purpose: Atacicept targets the B-cell stimulating factors, BLyS and APRIL, and has demonstrated a clinical response in SLE patients (pts) with high disease activity (HDA;…
Abstract Number: 2586 • 2017 ACR/ARHP Annual Meeting
Exposure-Response Modelling and Exposure-Safety Modelling Analyses in Two Phase II Studies of Atacicept in SLE
Orestis Papasouliotis¹, Oezkan Yalkinoglu¹, Cristina Vazquez-Mateo², Stephen Wax³, Amy H. Kao², Peter Chang³, Patricia Fleuranceau-morel² and Lisa Mahnke², ¹Merck KGaA, Darmstadt, Germany, ²EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ³EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA
Background/Purpose: Atacicept targets the B-cell stimulating factors BLyS and APRIL, and has been shown to reduce SLE disease activity. Our analyses evaluated the exposure-response and…
Abstract Number: 2587 • 2017 ACR/ARHP Annual Meeting
KZR-616, a Selective Inhibitor of the Immunoproteasome, Shows a Promising Safety and Target Inhibition Profile in a Phase I, Double-Blind, Single (SAD) and Multiple Ascending Dose (MAD) Study in Healthy Volunteers
Jason Lickliter¹, Janet Anderl², Christopher J Kirk³, Jinhai Wang⁴ and Darrin Bomba⁵, ¹Nucleus Network, Melbourne, Australia, ²Biology, Kezar Life Sciences, South San Francisco, CA, ³Kezar Life Sciences, South San Francisco, CA, ⁴DMPK, Kezar Life Sciences, South San Francisco, CA, ⁵Clinical Operations, Kezar Life Sciences, South San Francisco, CA
Background/Purpose: Proteasome inhibition is a standard of care for plasma cell malignancies. The first-generation inhibitor, bortezomib (BTZ), targets the constitutive proteasome and immunoproteasome and has…
Abstract Number: 2588 • 2017 ACR/ARHP Annual Meeting
Early Exposure to Hydroxychloroquine Predicts Good Renal Response in Japanese Patients with Lupus Nephritis Class III or IV
Tomofumi Kiyokawa¹, Hironari Hanaoka², Harunobu Iida¹, Yukiko Takakuwa¹ and Kimito Kawahata¹, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Division of Rheumatology and Allergology, Department of Internal Medicine,, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: The guideline or recommendation for lupus nephritis (LN) has been recently established by both ACR and EULAR, and hydroxychloriquine (HCQ) is recommended for all…
Abstract Number: 2589 • 2017 ACR/ARHP Annual Meeting
Functional and Mechanistic Characterization of Anifrolumab, a Fully Human Monoclonal Antibody Targeting the Interferon Alpha Receptor 1 for the Treatment of SLE
Gary P. Sims¹, Jeffrey Riggs², Richard Hanna¹, Bhargavi Rajan³, Jodi Karnell¹, Kamelia Zerrouki¹, Divya Sagar¹, Inna Vainshtein³, Erika Farmer⁴, Meina Liang³, Miguel A. Sanjuan¹ and Roland Kolbeck¹, ¹Respiratory, Inflammation and Autoimmunity (RIA), MedImmune, LLC, Gaithersburg, MD, ²Respiratory, Inflammation and Autoimmunity (RIA), MedImmune LLC, Gaithersburg, MD, ³MedImmune, LLC, Mountain View, CA, ⁴Analytical Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Increased type I interferon (IFN) activity is associated with the pathogenesis of SLE. Anifrolumab, a fully human immunoglobulin (Ig) G1 κ monoclonal antibody in clinical…
Abstract Number: 2590 • 2017 ACR/ARHP Annual Meeting
Subcutaneous Belimumab Plus Standard of Care Demonstrated Improvement in Multiple Organ Domains Versus Placebo Plus Standard of Care in Patients with Active Systemic Lupus Erythematosus (SLE)
Andrea Doria¹, Bonnie Pobiner², William Eastman³, Milena Kurtinecz⁴, Anne Hammer², James Groark⁵ and Damon Bass⁵, ¹Division of Rheumatology, University of Padova, Padova, Italy, ²GSK Research Triangle Park, Research Triangle Park, NC, ³GSK, Research Triangle Park, NC, ⁴GSK, Philadelphia, PA, ⁵GSK Collegeville, Collegeville, PA
Background/Purpose : Organ manifestation domain score improvement was assessed with subcutaneous (SC) belimumab (BEL) plus standard SLE care (SoC) in active, autoantibody-positive SLE. Methods: BLISS-SC…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].